Structural Heart Imaging (SHI) Market Overview
The structural heart imaging (shi) market size is expected to grow from USD 11938.66 million in 2025 to USD 12714.67 million in 2026 and is forecast to reach USD 23053.48 million by 2035 at 6.5% CAGR over 2026-2035.
Structural heart imaging is becoming increasingly central to the diagnosis, planning, guidance, and follow-up of minimally invasive cardiac procedures as hospitals manage an expanding population with valvular disorders, congenital abnormalities, and age-related structural heart disease. Cardiovascular conditions are associated with more than 20 million deaths worldwide each year, while mitral regurgitation alone is estimated to affect more than 35 million adults globally. Imaging requirements are also rising with the expansion of transcatheter therapies, where echocardiogram and angiogram technologies provide anatomical assessment, device positioning support, blood-flow visualization, and immediate verification of procedural outcomes. The technology environment is shifting rapidly toward 3D and 4D visualization, intracardiac echocardiography, automated measurements, multimodality fusion, and artificial intelligence. Modern cardiovascular ultrasound systems can now perform more than 5,600 AI-powered quantifications, while advanced cardiac view-classification algorithms have demonstrated accuracy approaching 99% for selected workflows. These capabilities are reducing repetitive measurements and helping imaging teams manage increasingly complex case volumes.
The United States remains one of the most advanced structural heart imaging environments because of high procedure volumes, extensive catheterization-laboratory infrastructure, established reimbursement pathways, and rapid adoption of image-guided therapies. Cardiovascular disease continues to cause more than 900,000 deaths annually in the country when multiple cardiovascular causes are considered, while more than 2 million Americans are estimated to be affected by clinically significant mitral regurgitation. The U.S. performs more than 100,000 transcatheter aortic valve replacement procedures in a typical recent year, creating sustained requirements for pre-procedural echocardiographic assessment, angiographic guidance, and post-implant imaging. Structural heart centers are increasingly combining live ultrasound and X-ray guidance within the same procedural workflow. FDA clearance of AI-supported structural heart guidance technologies in 2026 further strengthened this transition, particularly for mitral valve repair procedures in which operators must coordinate multiple image planes and continuously position devices within a moving cardiac structure.
Download Free sample to learn more about this report.
Key Findings
- Leading Product Type: Echocardiogram is expected to retain the leading position, representing approximately 60% of structural heart imaging demand as 3D, 4D, transesophageal, and intracardiac techniques become increasingly embedded in valve assessment and interventional guidance.
- Leading Application: Adult applications are projected to account for approximately 75% of demand, supported by the concentration of degenerative valvular disease among older populations and the continuing expansion of transcatheter interventions for aortic, mitral, and tricuspid conditions.
- Leading Region: North America is expected to lead with approximately 38% market share, supported by more than 100,000 annual U.S. transcatheter aortic valve replacement procedures and extensive adoption of advanced echocardiographic and angiographic systems in tertiary cardiac centers.
- Fastest Growing Region: Asia-Pacific is positioned for the fastest expansion, with India alone expected to record growth of approximately 8.1% between 2025 and 2030 as cardiac centers expand advanced imaging capacity and minimally invasive treatment availability.
- Technology Trend: AI-assisted echocardiography is reshaping clinical workflows, with current premium cardiovascular ultrasound platforms providing more than 5,600 AI-powered quantifications and automated view recognition to improve reproducibility, reduce repetitive measurements, and support complex structural heart examinations.
- Market Driver: The rising burden of valvular heart disease remains the strongest demand catalyst, with mitral regurgitation affecting more than 35 million adults worldwide and generating substantial requirements for diagnostic imaging, intervention planning, device guidance, and longitudinal follow-up.
- Competitive Landscape: Competition is increasingly centered on AI-enabled image fusion and intracardiac visualization, highlighted by a 2026 U.S. clearance for software that combines live ultrasound and X-ray guidance while automatically tracking devices during complex minimally invasive mitral repair procedures.
- Future Outlook: Structural heart imaging will become increasingly integrated with minimally invasive care pathways through 2035, while next-generation angiographic platforms are already demonstrating protocols capable of reducing X-ray radiation exposure by more than 50% in selected interventional workflows.
Latest Trends
The most significant technology trend is the movement from conventional image acquisition toward intelligent, procedure-aware visualization. Cardiologists increasingly require imaging systems that can identify anatomy, automate measurements, display multiple planes, quantify valve structures, and fuse live ultrasound with fluoroscopy without interrupting the procedure. Premium cardiovascular ultrasound platforms introduced during the current technology cycle can provide more than 5,600 AI-supported quantifications, compared with hundreds of automated measurements available on earlier generations. Some systems classify 12 standard echocardiographic views and automatically position Doppler sampling on more than 20 anatomical and hemodynamic targets, with reported classification accuracy near 99% in specified applications. Four-dimensional intracardiac echocardiography is also becoming more important because it allows physicians to visualize structures directly from within the heart while avoiding some limitations associated with transesophageal guidance. The newest ICE catheters support biplane views, multiplanar reconstruction, real-time color Doppler, and device navigation during structural interventions.
A second major trend is the convergence of echocardiogram and angiogram workflows around integrated interventional platforms. Complex mitral, tricuspid, left atrial appendage, and valve-replacement procedures require teams to interpret multiple image sources simultaneously, creating demand for systems capable of combining live ultrasound and X-ray information in a unified display. AI is increasingly being applied to this fusion environment, with 2026 technology releases offering automated device visualization during minimally invasive valve repair. Radiation management is advancing at the same time: newly introduced angiographic imaging protocols can use more than 50% less X-ray radiation than earlier low-dose configurations in selected coronary procedures, indicating the direction of future structural heart platforms. Intracardiac echocardiography is also expanding geographically. A 3D ICE catheter introduced more broadly in Europe in 2025 uses a miniature ultrasound element approximately 3 millimeters in diameter, demonstrating how manufacturers are reducing device dimensions while increasing real-time image detail and procedural versatility.
Market Dynamics
Driver
"Rising structural heart procedure volumes are increasing demand for precise multimodality imaging."
The principal market driver is the rising clinical burden of valve disease combined with the transition from open surgery toward catheter-based treatment. Mitral regurgitation affects more than 35 million adults worldwide, including more than 2 million people in the United States, while degenerative aortic stenosis becomes considerably more common in populations aged 75 years and above. Structural heart interventions require precise imaging at several stages: patient selection, anatomical measurement, procedural planning, catheter navigation, device deployment, leak detection, and follow-up. The United States alone conducts more than 100,000 transcatheter aortic valve replacement procedures during a typical recent year, and growth in mitral and tricuspid interventions is broadening the addressable imaging workload. As structural heart treatment expands beyond aortic valves, imaging complexity rises because operators require detailed assessment of leaflet morphology, annular dimensions, blood flow, device orientation, and residual regurgitation during the same procedure.
Aging demographics reinforce this demand. The global population aged 65 years and older is expected to exceed 1.5 billion by 2050, increasing the number of patients requiring evaluation for degenerative valve conditions. Hospitals are responding through investments in 3D transesophageal imaging, 4D intracardiac echocardiography, advanced angiography, and AI-based quantification. Structural heart interventions have been projected in industry technology assessments to expand at rates around 9% annually in selected procedure categories, outpacing several conventional cardiovascular imaging segments. This environment favors suppliers capable of supporting diagnosis and treatment through one integrated workflow rather than offering isolated imaging equipment. The need to increase procedure capacity without proportionately increasing specialist staffing is also accelerating interest in automated measurements and standardized acquisition tools.
Restraint
"Capital intensity and specialist requirements constrain adoption outside major cardiac centers."
Advanced structural heart imaging remains concentrated in tertiary hospitals because sophisticated systems require substantial infrastructure, specialized operators, ongoing software upgrades, catheterization facilities, and rigorous quality-control programs. A structural heart program may use 3D or 4D echocardiography, transesophageal probes, intracardiac catheters, angiography, image-fusion software, hemodynamic monitoring, and multimodality planning tools within the same clinical pathway. Consequently, smaller facilities face a considerably higher implementation burden than centers performing conventional 2D echocardiography. Emerging markets continue to show significant differences between metropolitan and rural access, with advanced cardiac imaging penetration in some rural healthcare environments remaining below 35%. These disparities restrict procedure availability and slow the diffusion of high-end imaging systems despite growing disease prevalence.
Workforce availability creates another restraint. Advanced imaging requires cardiologists, echocardiographers, sonographers, interventional specialists, anesthesiology teams, and technical staff who understand increasingly sophisticated platforms. Pediatric structural heart imaging introduces an additional expertise requirement because congenital anatomy varies substantially between patients and approximately 1 in 100 live births is affected by some form of congenital heart defect. Manufacturers are attempting to reduce this burden through automation: premium ultrasound platforms now provide more than 5,600 AI-powered quantifications and automated cardiac view recognition. Nevertheless, AI remains an assistive technology and does not eliminate the need for experienced clinical interpretation. Training, credentialing, procedural coordination, and system integration therefore remain important barriers to rapid adoption, particularly in facilities with lower annual structural intervention volumes.
Opportunity
"AI, 4D intracardiac imaging, and emerging-market expansion are opening new adoption pathways."
The strongest opportunity lies in transforming structural heart imaging from a specialist-dependent workflow into a more standardized, integrated, and scalable clinical process. AI-supported systems are already demonstrating automated cardiac view recognition, chamber contouring, Doppler placement, device tracking, and quantitative measurements. Certain current cardiovascular ultrasound platforms offer more than 5,600 AI-supported measurements and report approximately 99% accuracy for selected view-classification functions. These capabilities can reduce repetitive manual actions and potentially allow imaging teams to handle larger examination volumes without compromising standardization. The opportunity is particularly relevant as structural heart centers expand mitral and tricuspid interventions, where anatomical complexity requires rapid interpretation of multiple image planes. Software that automatically aligns ultrasound information with interventional devices may gradually become a standard component of high-volume catheterization laboratories.
Geographic expansion creates another substantial opportunity. Asia-Pacific has a large cardiovascular patient population but remains unevenly penetrated by advanced structural imaging systems. India is expected to record structural heart imaging growth of approximately 8.1% over the latter half of the decade in widely tracked industry estimates, while urban cardiac centers across China, India, Southeast Asia, and other developing markets continue to expand catheterization and valve-treatment capacity. Pediatric imaging also represents a meaningful long-term opportunity because congenital heart disease occurs in approximately 1% of live births and requires repeated imaging throughout diagnosis, treatment, and follow-up. Portable systems, cloud-enabled review, automated quantification, and remote clinical collaboration could extend advanced capabilities beyond major academic hospitals and create new demand among regional cardiac centers.
Challenge
"Multimodality complexity and clinical variability make consistent imaging performance difficult to achieve."
A major challenge is the coordination of multiple imaging technologies during increasingly complex procedures. Structural heart teams may use transesophageal echocardiography, intracardiac echocardiography, angiography, Doppler imaging, fluoroscopy, and previously acquired anatomical datasets within a single intervention. Even when systems are technically compatible, clinicians must maintain correct spatial orientation while the heart is moving and the interventional device is changing position. During mitral valve repair, for example, the echocardiographer and interventional cardiologist traditionally interpret live ultrasound and X-ray views on multiple displays while coordinating device trajectory. AI-guided fusion technologies introduced in 2026 are intended to simplify this process, but their effective implementation requires compatible equipment, training, validated workflows, and continuing clinical oversight.
Image quality variability presents an additional challenge because patient anatomy, acoustic windows, heart rhythm, obesity, calcification, implants, and operator technique can influence results. Automated systems can improve reproducibility but cannot remove every limitation. Manufacturers are therefore investing heavily in larger training datasets and multimodal algorithms. One leading cardiovascular ultrasound platform was developed using more than 2 billion annotated cardiac images and supports thousands of automated quantifications, illustrating the scale of data required to improve consistency. Radiation exposure remains another operational consideration for angiogram-based guidance. Recent low-dose technology can reduce exposure by more than 50% in specified interventional configurations, yet dose optimization must remain balanced with sufficient image quality for device guidance. Maintaining this balance across varying patient characteristics and complex procedures will continue to influence purchasing decisions.
Download Free sample to learn more about this report.
Segmentation Analysis
The structural heart imaging market is segmented by product type into Echocardiogram and Angiogram and by application into Adult and Child. Echocardiogram technology accounts for approximately 60% of current structural imaging activity in the supplied segmentation framework because ultrasound provides real-time anatomical and hemodynamic information without ionizing radiation. Angiogram technology represents approximately 40%, supported by its essential role in catheter-based interventions and device deployment. Application demand is more concentrated, with Adult accounting for approximately 75% and Child representing approximately 25%. The distribution reflects the high prevalence of degenerative structural heart disease among older adults while recognizing the substantial recurring imaging requirements associated with congenital cardiac abnormalities in children.
By Types
Echocardiogram: Echocardiogram holds approximately 60% market share within the supplied product segmentation and remains the primary structural heart imaging technology because it combines anatomical visualization with real-time assessment of valve motion, chamber function, blood-flow velocity, pressure gradients, and regurgitation. The segment is being strengthened by 3D transesophageal echocardiography and 4D intracardiac imaging, which provide detailed views during valve repair, replacement, and closure procedures. Recent cardiovascular ultrasound systems can deliver more than 5,600 AI-powered quantifications, while selected view-recognition algorithms report approximately 99% classification accuracy. New intracardiac platforms also provide real-time 4D color Doppler and multiplanar reconstruction, reducing dependence on repeated probe repositioning. A 3D ICE catheter expanded into Europe in 2025 incorporates an ultrasound element only about 3 millimeters in diameter, demonstrating continued miniaturization and broadening the use of echocardiographic guidance during minimally invasive structural heart interventions.
Angiogram: Angiogram accounts for approximately 40% market share within the supplied product segmentation and remains indispensable in catheterization laboratories because fluoroscopic X-ray imaging allows physicians to visualize guidewires, catheters, implanted devices, vascular access, and contrast-enhanced anatomical structures in real time. The segment is evolving beyond standalone fluoroscopy toward integrated image-guided therapy platforms that combine angiography with ultrasound, hemodynamic information, and AI assistance. Contemporary 2D and 3D fusion technologies can overlay anatomical landmarks onto live fluoroscopic images and update information as the C-arm or procedural table changes position. Radiation management is receiving greater attention, with a 2026 generation of angiographic technology offering an ultra-low-dose protocol using more than 50% less X-ray radiation than earlier low-dose settings for specified interventional workflows. Such improvements support continuing use of angiography as structural heart procedure volumes increase while healthcare systems place greater emphasis on staff and patient exposure.
By Applications
Adult: Adult applications account for approximately 75% market share, reflecting the large burden of age-related aortic stenosis, mitral regurgitation, tricuspid disease, atrial structural abnormalities, and other conditions requiring detailed cardiac imaging. Mitral regurgitation affects more than 35 million adults globally, and more than 2 million affected individuals are estimated in the United States alone. Structural imaging demand rises significantly as patients progress from diagnosis to intervention because transcatheter therapies require repeated assessment before, during, and after device placement. More than 100,000 transcatheter aortic valve replacement procedures are performed annually in the U.S. in recent years, while minimally invasive mitral and tricuspid interventions are expanding the range of cases requiring advanced echocardiographic and angiographic support. Population aging will keep adult applications dominant, with more than 1.5 billion people worldwide projected to be aged 65 years or older by 2050.
Child: Child applications represent approximately 25% market share within the supplied application structure. Demand is primarily associated with congenital heart abnormalities, pediatric valve disorders, postoperative monitoring, and long-term surveillance of patients receiving corrective or palliative procedures. Congenital heart defects affect approximately 1 in 100 live births worldwide, creating a persistent requirement for safe, repeatable, non-invasive imaging. Echocardiography remains particularly important because it avoids ionizing radiation and can provide anatomical and hemodynamic information during repeated examinations. Technology development is also improving pediatric image quality through higher frame rates, smaller transducers, AI-assisted measurements, and more sensitive Doppler capabilities. Although pediatric interventional volumes remain below adult procedure levels, children may require multiple imaging examinations over several years, creating stable long-term demand for specialized structural heart imaging capabilities in children's hospitals and congenital cardiac centers.
Download Free sampleto learn more about this report.
Regional Outlook
North America
North America is expected to retain approximately 38% of the structural heart imaging market, making it the leading regional market during the forecast period. The United States contributes the majority of regional demand through extensive echocardiography infrastructure, high adoption of catheter-based structural interventions, advanced reimbursement systems, and a large network of tertiary cardiovascular centers. More than 100,000 transcatheter aortic valve replacement procedures are conducted annually in the U.S. in recent years, and mitral regurgitation affects more than 2 million American adults. These patient and procedural volumes support sustained utilization of premium echocardiography, angiography, image-fusion software, and intracardiac imaging technologies.
The region is also an important launch market for AI-based structural heart technologies. In March 2026, an AI-enabled image-guidance solution received U.S. FDA clearance for use in complex minimally invasive mitral valve repair guidance, combining live echocardiographic and X-ray images while automatically tracking a repair device. The continued modernization of cath labs is pushing hospitals toward integrated technology ecosystems rather than separate imaging platforms. North American demand is therefore increasingly influenced by software interoperability, automated quantification, real-time device visualization, reduced radiation exposure, and procedural efficiency. The concentration of high-volume structural heart centers also enables manufacturers to validate new imaging workflows more quickly than in markets where intervention volumes remain comparatively fragmented.
Europe
Europe is estimated to account for approximately 30% of structural heart imaging demand and maintains a strong clinical base for transcatheter valve therapy, echocardiographic innovation, and multimodality imaging. An aging population and high burden of cardiovascular disease support continued examination volumes, while established structural heart programs in Germany, France, Italy, the United Kingdom, the Netherlands, Scandinavia, and other European countries create demand for premium systems. European centers have been early adopters of 3D transesophageal imaging and fusion-guided intervention, and the growing treatment of mitral and tricuspid disease is increasing the importance of real-time anatomical visualization beyond conventional aortic valve workflows.
The region is also becoming an important market for intracardiac echocardiography. In May 2025, a leading imaging supplier expanded availability of a real-time 3D ICE catheter in Europe, using a miniaturized ultrasound probe approximately 3 millimeters in diameter. The technology provides live 2D and 3D imaging from within the cardiac chambers and can reduce reliance on more invasive imaging approaches in selected procedures. European hospitals are simultaneously focusing on procedure efficiency and staffing pressure, increasing interest in AI automation and standardized measurements. As regulators and hospitals continue to emphasize radiation safety, integrated echocardiogram and angiogram workflows with advanced dose-management features are also expected to gain importance through 2035.
Asia-Pacific
Asia-Pacific is expected to account for approximately 22% of structural heart imaging demand while registering the fastest regional growth over the forecast period. The region combines large patient populations with substantial variation in healthcare access, allowing advanced urban cardiac centers and underserved secondary markets to expand simultaneously. India is expected to record growth of approximately 8.1% between 2025 and 2030 in structural heart imaging, reflecting increasing diagnostic capacity and adoption of minimally invasive cardiac procedures. China, Japan, South Korea, India, Australia, and major Southeast Asian economies are expanding cardiovascular imaging infrastructure while hospitals increasingly adopt digital reporting, AI-enabled echocardiography, and advanced catheterization laboratories.
The long-term opportunity is particularly significant because advanced imaging penetration outside large urban areas remains lower than in North America and Western Europe. In several developing healthcare environments, access to sophisticated cardiac imaging in rural populations remains below 35%, leaving substantial room for portable echocardiography, cloud-based review, automated measurements, and regional referral networks. Manufacturers are also expanding localized product introductions. A leading cardiovascular ultrasound platform supporting structural heart, pediatric, diagnostic, and electrophysiology applications was formally introduced at an Asia-Pacific echocardiography meeting in Vietnam in October 2025 with participation from more than 50 cardiologists and specialists. Growing training programs and technology partnerships are expected to accelerate adoption as procedure volumes increase.
Middle East & Africa
Middle East & Africa represents approximately 10% of structural heart imaging demand within the current regional structure, but the market is characterized by significant differences between highly equipped metropolitan hospitals and healthcare systems with limited specialist access. Major medical centers in Gulf countries and selected African cities increasingly operate advanced cath labs and cardiac surgery programs, creating demand for 3D echocardiography, angiography, and structural intervention guidance. In less-developed areas, however, access to specialized cardiac imaging can remain below 30% of the relevant healthcare network, limiting early diagnosis and referral of complex valve and congenital heart conditions.
Future growth will depend on expanding cardiac-care infrastructure, workforce training, and access to lower-complexity imaging platforms. Portable echocardiography and AI-assisted acquisition may be particularly important because automated tools can support standardized examinations where specialist availability is limited. Congenital heart defects occur in approximately 1% of live births globally, creating persistent pediatric imaging needs across the region. At the same time, cardiovascular diseases account for a substantial portion of premature adult mortality in many Middle Eastern and African countries. As tertiary centers increase the number of catheter-based interventions, adoption is expected to gradually shift from basic diagnostic imaging toward integrated structural heart workflows combining echocardiogram and angiogram capabilities.
List of Top Structural Heart Imaging (SHI) Companies
- CardioComm Solutions Inc.
- Circle Cardiovascular Imaging, Inc.
- HeartSciences
- Koninklijke Philips N.V.
- Pie Medical Imaging
- Shimadzu Corporation
- Siemens Healthineers
- TomTec Imaging Systems GmbH
- Toshiba Corporation
Top 2 Companies Market Share
Siemens Healthineers: The current ACUSON Origin platform includes more than 5,600 AI-powered quantifications, while its AI functions were developed using more than 2 billion annotated cardiac images. The system also supports 2D and 4D TEE and ICE workflows. The company's fourth-generation AcuNav Lumos 4D ICE technology adds biplane imaging and real-time 4D color Doppler, strengthening its presence in complex structural heart procedures.
Koninklijke Philips N.V.: Koninklijke Philips N.V. is estimated to hold approximately 22% share within the same competitive framework, giving the top 2 participants a combined share of approximately 48%. Philips has strengthened its structural heart position through EPIQ cardiovascular ultrasound, Azurion image-guided therapy, EchoNavigator fusion imaging, and VeriSight Pro 3D ICE. In 2025, the company expanded VeriSight Pro into Europe using an ultrasound probe approximately 3 millimeters in diameter.
Investment Analysis
Investment priorities are moving toward integrated cardiovascular platforms rather than individual diagnostic devices. Hospitals increasingly need systems capable of supporting a patient from initial echocardiographic evaluation through interventional planning, angiographic guidance, device placement, and post-procedure follow-up. This creates attractive investment potential in AI-assisted quantification, image fusion, intracardiac echocardiography, workflow software, and dose-management technologies. Structural heart intervention categories have been projected to grow at rates near 9% annually in selected technology assessments, supporting continued capital spending on catheterization laboratories and premium cardiac ultrasound. Vendors are consequently directing product development toward automation and interoperability. Current platforms providing more than 5,600 AI-supported quantifications illustrate how software capability is becoming as important as transducer and detector performance when health systems evaluate long-term technology investments.
Emerging economies offer another investment opportunity as advanced structural heart services expand beyond top metropolitan hospitals. India's structural heart imaging market has been projected to advance approximately 8.1% from 2025 to 2030, exceeding growth levels in many mature markets. Investment is likely to concentrate on scalable cardiac ultrasound, angiographic systems, hybrid procedural infrastructure, cloud-based analysis, and clinician training. Pediatric care provides additional demand because congenital heart defects affect approximately 1 in 100 births and may require multiple imaging examinations over a patient's lifetime. Investors and manufacturers must nevertheless account for uneven reimbursement, specialist shortages, and infrastructure limitations. Strategies combining equipment, software, education, and service support are therefore likely to achieve broader adoption than standalone capital-equipment sales.
New Product Development
New product development is focused on increasing the amount of clinically useful information available during a procedure while reducing operator workload. Artificial intelligence is being embedded directly into cardiovascular ultrasound and image-guided therapy systems for view recognition, valve quantification, chamber contouring, Doppler placement, and device tracking. Siemens Healthineers' current cardiovascular ultrasound architecture provides more than 5,600 AI-powered quantifications, with selected algorithms achieving approximately 99% accuracy in predefined view-classification tasks. Philips has advanced real-time fusion guidance through DeviceGuide, which received FDA clearance in March 2026 and combines live ultrasound and X-ray information to automatically visualize a mitral repair device. These developments illustrate a broader shift from passive imaging systems toward technologies that interpret procedural context and provide interactive assistance while leaving final clinical decisions with physicians.
Miniaturization and dose reduction represent equally important development priorities. The VeriSight Pro 3D ICE catheter introduced in Europe in May 2025 incorporates an approximately 3-millimeter ultrasound probe capable of supplying live 2D and 3D intracardiac images, supporting the growing use of imaging from within the heart. Siemens Healthineers' AcuNav Lumos 4D ICE catheter adds biplane imaging, multiplanar reconstruction, and real-time 4D color Doppler for structural and electrophysiology procedures. On the angiography side, Philips introduced SmartIQ in May 2026 with an ultra-low-dose protocol capable of using more than 50% less X-ray radiation than previous low-dose settings in specified applications. Future systems are expected to combine these advances with more automated anatomical recognition, workflow orchestration, and multimodality data synchronization.
Five Recent Developments
- March 2026: Koninklijke Philips N.V. received U.S. FDA 510(k) clearance for EchoNavigator R5.0 with DeviceGuide, an AI-assisted structural heart guidance solution. The system combines live echocardiography and X-ray imaging and automatically visualizes a mitral repair device during minimally invasive procedures. Mitral regurgitation affects more than 35 million adults worldwide, highlighting the clinical population targeted by increasingly sophisticated procedural guidance technologies.
- May 2026: Koninklijke Philips N.V. introduced SmartIQ imaging technology for its Azurion image-guided therapy platform. The newly developed ultra-low-dose protocol is capable of employing more than 50% less X-ray radiation than the company's previous low-dose configuration in specified coronary procedures. Although introduced for coronary applications, the development demonstrates the dose-management direction of image-guided cardiovascular systems that are also increasingly used within integrated structural heart environments.
- May 2025: Koninklijke Philips N.V. expanded VeriSight Pro 3D intracardiac echocardiography into Europe. The catheter incorporates a miniature ultrasound element approximately 3 millimeters in diameter and delivers real-time 2D and 3D visualization from inside cardiac chambers. The technology supports minimally invasive structural heart procedures and can reduce reliance on transesophageal imaging and general anesthesia for selected patients and procedural workflows.
- August 2024: Siemens Healthineers announced U.S. FDA clearance for ACUSON Origin and the AcuNav Lumos 4D ICE catheter. ACUSON Origin provides more than 5,600 AI-powered cardiovascular quantifications and uses algorithms trained on more than 2 billion annotated cardiac images. AcuNav Lumos adds advanced biplane imaging and real-time 4D color Doppler, expanding procedural visualization for structural heart and electrophysiology applications.
- April 2024: Siemens Healthineers expanded the commercialization of ACUSON Origin in Asian markets, introducing an AI-driven cardiovascular ultrasound workflow capable of automating approximately 120 commonly required measurements through AI Measure while supporting 2D and 4D heart analysis. The platform's broader rollout strengthened competition around automation, standardized quantification, and structural heart imaging efficiency as hospitals addressed increasing cardiovascular examination volumes.
Report Coverage
This Structural Heart Imaging (SHI) Market report evaluates the industry across the 2026-2035 forecast period using 2025 as the principal baseline for market assessment. Coverage includes the supplied product categories Echocardiogram and Angiogram, alongside the Adult and Child application segments. The analysis assesses market direction through procedure expansion, aging demographics, congenital disease incidence, hospital imaging investment, AI adoption, multimodality fusion, intracardiac echocardiography, radiation management, and regional infrastructure development. Segment estimates indicate approximately 60% share for Echocardiogram and 40% for Angiogram, while Adult applications account for approximately 75% and Child applications represent approximately 25%. Regional assessment covers North America at approximately 38%, Europe at 30%, Asia-Pacific at 22%, and Middle East & Africa at 10%, providing a consistent view of mature and emerging structural heart imaging environments.
The competitive coverage examines CardioComm Solutions Inc., Circle Cardiovascular Imaging, Inc., HeartSciences, Koninklijke Philips N.V., Pie Medical Imaging, Shimadzu Corporation, Siemens Healthineers, TomTec Imaging Systems GmbH, and Toshiba Corporation. The analysis emphasizes technologies and strategic developments that are currently changing purchasing decisions, including cardiovascular ultrasound platforms with more than 5,600 AI-powered quantifications, AI-supported device tracking cleared in 2026, approximately 3-millimeter 3D intracardiac ultrasound technology introduced more broadly in Europe during 2025, and angiographic dose-management innovations capable of exceeding 50% radiation reduction in specified workflows. The report also evaluates investment priorities, product development, clinical workflow constraints, workforce requirements, regional access differences, and opportunities created by continued growth in minimally invasive structural heart interventions through 2035.
| REPORT COVERAGE | DETAILS |
|---|---|
|
Market Size Value In |
US$ 12714.67 Million in 2026 |
|
Market Size Value By |
US$ 23053.48 Million by 2035 |
|
Growth Rate |
CAGR of 6.5 % from 2026 to 2035 |
|
Forecast Period |
2026 to 2035 |
|
Base Year |
2025 |
|
Historical Data Available |
2021-2024 |
|
Regional Scope |
Global |
|
Segments Covered |
Type and Application |
Related Reports
-
What will be the projected value of Structural Heart Imaging (SHI) Market by 2035?
The Structural Heart Imaging (SHI) Market is projected to reach USD 23053.48 Million by 2035, expanding at a steady pace during the forecast period. Market growth is supported by rising demand, technological advancements, and increasing adoption across major end-use industries worldwide.
-
What is the expected CAGR of the Structural Heart Imaging (SHI) Market during 2026-2035?
The Structural Heart Imaging (SHI) Market is expected to grow at a CAGR of 6.5% during the forecast period from 2026 to 2035.
-
Which companies are leading the Structural Heart Imaging (SHI) Market?
Key players in the Structural Heart Imaging (SHI) Market market include CardioComm Solutions Inc., Circle Cardiovascular Imaging, Inc., HeartSciences, Koninklijke Philips N.V., Pie Medical Imaging, Shimadzu Corporation, Siemens Healthineers, TomTec Imaging Systems GmbH, Toshiba Corporation
-
How large was the Structural Heart Imaging (SHI) Market in 2025?
The Structural Heart Imaging (SHI) Market was valued at USD 11938.66 Million in 2025, reflecting strong demand and continued adoption across major industries.
